Abstract 4090: Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor
Leviten, Dina, Sierra, Teresa, Dozier, Ashley, Boyce, Richard, Boyle, Bob, Peterson, Scott, Vo, Alex C.
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article
Abstract 297: The novel orally available sub-nanomolar potent and selective checkpoint kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma as a single agent and in combination with Wee1 inhibition
Rosler, Robert, Taylor, Janelle, Leviten, Dina, Sierra, Teresa, Dozier, Ashley, Klucher, Kevin, Boyce, Rich, Boyle, Bob, Vo, Alex, Peterson, Scott
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article
Abstract 295: CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition
Vo, Alex, Taylor, Janelle, Rosler, Robert, Piasecki, Julia, Leviten, Dina, Sierra, Teresa, Dozier, Ashley, Klucher, Kevin, Boyle, Bob, Boyce, Rich, Peterson, Scott
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article